Cromwell Holdings LLC Buys New Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cromwell Holdings LLC purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,600 shares of the company’s stock, valued at approximately $61,000.

Other institutional investors have also added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new position in Takeda Pharmaceutical during the 3rd quarter valued at approximately $601,000. Verition Fund Management LLC purchased a new position in Takeda Pharmaceutical during the 3rd quarter valued at approximately $1,533,000. HighTower Advisors LLC grew its holdings in Takeda Pharmaceutical by 199.5% during the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock valued at $1,744,000 after buying an additional 81,653 shares in the last quarter. XTX Topco Ltd purchased a new position in Takeda Pharmaceutical during the 3rd quarter valued at approximately $957,000. Finally, Creative Planning grew its holdings in Takeda Pharmaceutical by 46.3% during the 3rd quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after buying an additional 49,871 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.86 on Friday. The stock has a market capitalization of $44.08 billion, a PE ratio of 34.64, a P/E/G ratio of 0.24 and a beta of 0.51. The business has a 50 day simple moving average of $13.28 and a two-hundred day simple moving average of $13.87. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.